switched from semaglutide to tirzepatide Switching Tirzepatide and Semaglutide key differences,

Discontinuation rates due to adverse events in major trials were relatively low, generally under 10%, but higher than placebo

[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Shaw BH, Stiles LE, Bourne K, Green EA, Shibao CA, Okamoto LE, Garland EM, Gamboa A, Diedrich A, Raj V, Sheldon RS, Biaggioni I, Robertson D and Raj SR

The GIP pathway improves fat oxidation and energy expenditure

Given the medication's relatively recent approvalMounjaro in May 2022 and Zepbound in November 2023ongoing post-marketing surveillance continues to evaluate long-term safety outcomes, including potential associations with serious adverse events such as malignancy